

Leqvio - Home - HCP

[Prescribing information](#)

Image



Image



LEQVIO® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:<sup>1</sup>

- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

**For full safety information, please refer to the LEQVIO® Summary of Product Characteristics.**

---

# LEQVIO®▼ (inclisiran)

**LEQVIO® is recommended by NICE, within its licensed indication, as an option for the treatment of eligible adult patients who:<sup>2</sup>**

Image

1

**Have already had certain cardiovascular events** (acute coronary syndrome such as MI or unstable angina needing hospitalisation, coronary or other arterial revascularisation procedures, coronary heart disease, ischaemic stroke or PAD)

Image

2

**Have persistently elevated LDL-C levels ( $\geq 2.6$  mmol/L)** despite maximum tolerated statins with or without other lipid-lowering therapies, or other lipid-lowering therapies when statins are not tolerated or are contraindicated

---

Image



**Nearly 1 in 5 patients with cardiovascular disease do not have a**

**recorded current prescription of lipid-lowering therapy, remaining at high risk for cardiovascular events and death (n=472,650)\*<sup>3</sup>**

The effect of LEQVIO® on cardiovascular morbidity and mortality has not yet been determined.<sup>1</sup>

---

Image



**On average, LDL-C levels were reduced by ~50% from baseline (2.92±1.2 mmol/L) in eligible patients with ASCVD on LEQVIO® and a maximally tolerated statin in an observational study, which is consistent with the placebo-corrected results seen in the Phase III trials ORION-9, ORION-10 and ORION-11<sup>4-7</sup>**

---

Image



**In clinical trials, LEQVIO® had a safety profile similar to placebo, apart from injection-site reactions (8.2% and 1.8% of patients, respectively)<sup>1</sup>**

[Learn more about the safety data of LEQVIO®](#)

---

\*National CVDPREVENT data covering the period up to March 2022. Data was received from 96.6% of GP practices, including approximately 18 million patients.<sup>3</sup>

ASCVD, atherosclerotic cardiovascular disease; GP, general practitioner; LDL-C, low-density lipoprotein cholesterol; NICE, National Institute for Health and Care Excellence.

## **References**

1. LEQVIO® Summary of Product Characteristics.
2. National Institute for Health and Care Excellence. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. Available at: <https://www.nice.org.uk/guidance/ta733/resources/inclisiran-for->

[treating...](#) [Accessed January 2025].

3. Healthcare Quality Improvement Partnership. <https://www.hqip.org.uk/resource/third-annual-report-cvdprevent/> [Accessed January 2025].
4. Wright RS, et al. Oral presentation. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. ESC Congress 2023. Amsterdam, The Netherlands, 25–28 August 2023.
5. Raal FJ, et al. *N Engl J Med* 2020;382:1520–1530.
6. Ray KK, et al. *N Engl J Med* 2020;382:1507–1519.
7. Ray KK, et al. *Eur Heart J* 2022;43(48):5047–5057.

LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG. Licensed from Alnylam Pharmaceuticals, Inc.

UK | January 2025 | FA-11205529

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:** <https://www.pro.novartis.com/uk-en/medicines/cardio-metabolic/leqvio>